{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:05:45Z","timestamp":1789344345703,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005031","name":"Bhabha Atomic Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005031","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Axis Bank Center PhD Fellowship"},{"name":"Param Hansa Philanthropies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The cues that cause B cells to adopt a regulatory phenotype are unknown. We previously reported on the regulatory B-T axis in mouse fibrosarcoma. This work demonstrates the presence of TGF-\u03b2-generating Bregs in the sarcoma microenvironment as well as variable gene expression depending on TGF-\u03b2 levels. Breg depletion reduced tumor-evoked Bregs and progression of WEHI-164 fibrosarcoma, which was reversed by adoptive transfer of B cells. Tumor-derived PGE2 acting via EP4\/STAT3 signaling is a key driver of tBreg formation, ultimately resulting in increased Tregs. Only the TGF-\u03b2\n                    <jats:sup>+<\/jats:sup>\n                    tBregs caused T cell suppression. PGE2 activated STAT3 in a non-canonical manner since pre-treatment of B cells with JNK and NF-\u03baB inhibitors completely restored tBreg-induced T cell suppression. The COX-2 inhibitor NS-398 prevented the generation of tumor-evoked Bregs, resulting in a lower tumor burden, fewer Tregs, and improved T cell responses. TGF-\u03b2-producing Bregs were identified in sarcomas and other cancers with elevated PGE2. The B cells from PTGS2\n                    <jats:sup>hi<\/jats:sup>\n                    cancers displayed unique Breg signatures when compared to PTGS2\n                    <jats:sup>lo<\/jats:sup>\n                    cancers. TCGA analysis showed that the Breg signature was higher in patients with high PTGS2 levels, which was also associated with a poor survival rate. In summary, we found that the tumor-derived PGE2 activates non-canonical MAPK\/STAT3 in B cells, leading to the formation of TGF-\u03b2-generating Breg cells. PTGS2\n                    <jats:sup>hi<\/jats:sup>\n                    Breg\n                    <jats:sup>hi<\/jats:sup>\n                    patients were associated with a poor survival rate, while the COX-2 inhibitor NS-398 prevented tBreg generation and reduced tumor burden. This could lead to the development of novel strategies for reducing tBreg production in cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09045-w","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:17:33Z","timestamp":1782490653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TGF-\u03b2-producing tBregs are associated with poor survival rates in PTGS2-high cancers"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-0482","authenticated-orcid":false,"given":"Kavitha","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soundharya","family":"Ramu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-2109","authenticated-orcid":false,"given":"Mohit Kumar","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-3687","authenticated-orcid":false,"given":"Bhavani S.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"9045_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1517\/13543784.2015.1076792","volume":"24","author":"N Mohindra","year":"2015","unstructured":"Mohindra N, Agulnik M. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas. Expert Opin Investig Drugs. 2015;24:1409\u201318.","journal-title":"Expert Opin Investig Drugs"},{"key":"9045_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco.2018.08.04","volume":"7","author":"CC Yen","year":"2018","unstructured":"Yen CC, Chen TW. Next frontiers in systemic therapy for soft tissue sarcoma. Chin Clin Oncol. 2018;7:43.","journal-title":"Chin Clin Oncol"},{"key":"9045_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432\u20133.","journal-title":"Science"},{"key":"9045_CR4","unstructured":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950\u201365.e28."},{"key":"9045_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556\u201360.","journal-title":"Nature"},{"key":"9045_CR6","doi-asserted-by":"crossref","unstructured":"Kendal JK, Shehata MS, Lofftus SY, Crompton JG. Cancer-associated B cells in sarcoma. Cancers. 2023;15:622.","DOI":"10.3390\/cancers15030622"},{"key":"9045_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23915","volume":"10","author":"W Wu","year":"2024","unstructured":"Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P, et al. The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. Heliyon. 2024;10:e23915.","journal-title":"Heliyon"},{"key":"9045_CR8","doi-asserted-by":"publisher","unstructured":"Boulat V, Alberts E, Driscoll PC, Hung MS, Cunha A, Quist J, et al. Lactate blocks tertiary lymphoid structure formation by inhibiting B-cell chemotaxis. Preprint at https:\/\/doi.org\/10.1101\/2025.08.30.673054 2025.","DOI":"10.1101\/2025.08.30.673054"},{"key":"9045_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2215\/CJN.09430915","volume":"11","author":"W Hoffman","year":"2016","unstructured":"Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. Clin J Am Soc Nephrol. 2016;11:137\u201354.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9045_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/intimm\/dxz068","volume":"32","author":"Y Baba","year":"2020","unstructured":"Baba Y, Saito Y, Kotetsu Y. Heterogeneous subsets of B-lineage regulatory cells (Breg cells). Int Immunol. 2020;32:155\u201362.","journal-title":"Int Immunol"},{"key":"9045_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1074-7613(02)00274-1","volume":"16","author":"A Mizoguchi","year":"2002","unstructured":"Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002;16:219\u201330.","journal-title":"Immunity"},{"key":"9045_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/ni833","volume":"3","author":"S Fillatreau","year":"2002","unstructured":"Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944\u201350.","journal-title":"Nat Immunol"},{"key":"9045_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12939","volume":"299","author":"D Michaud","year":"2021","unstructured":"Michaud D, Steward CR, Mirlekar B, Pylayeva-Gupta Y. Regulatory B cells in cancer. Immunol Rev. 2021;299:74\u201392.","journal-title":"Immunol Rev"},{"key":"9045_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20:294\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"9045_CR15","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3892\/ol.2017.5810","volume":"13","author":"A Maglioco","year":"2017","unstructured":"Maglioco A, Machuca DG, Badano MN, Nannini P, Camerano GV, Costa H, et al. B cells inhibit the antitumor immunity against an established murine fibrosarcoma. Oncol Lett. 2017;13:3225\u201332.","journal-title":"Oncol Lett"},{"key":"9045_CR16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-12-4184","volume":"73","author":"M Bodogai","year":"2013","unstructured":"Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, et al. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 2013;73:2127\u201338.","journal-title":"Cancer Res"},{"key":"9045_CR17","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.18632\/oncotarget.22976","volume":"9","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Shen M, Feng Y, He R, Xu X, Xie Y, et al. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1\/PD-L1 pathway. Oncotarget. 2018;9:14803\u201314.","journal-title":"Oncotarget"},{"key":"9045_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1896658","volume":"10","author":"MA Smolle","year":"2021","unstructured":"Smolle MA, Herbsthofer L, Goda M, Granegger B, Brcic I, Bergovec M, et al. Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. Oncoimmunology. 2021;10:1896658.","journal-title":"Oncoimmunology"},{"key":"9045_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-020-02666-w","volume":"70","author":"K Premkumar","year":"2021","unstructured":"Premkumar K, Shankar BS. TGF-\u03b2R inhibitor SB431542 restores immune suppression induced by regulatory B-T cell axis and decreases tumour burden in murine fibrosarcoma. Cancer Immunol Immunother. 2021;70:153\u201368.","journal-title":"Cancer Immunol Immunother"},{"key":"9045_CR20","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1201920","volume":"190","author":"K Wejksza","year":"2013","unstructured":"Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, et al. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor \u03b1. J Immunol. 2013;190:2575\u201384.","journal-title":"J Immunol"},{"key":"9045_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41421-023-00568-6","volume":"9","author":"C Chen","year":"2023","unstructured":"Chen C, Ma J, Pi C, Huang W, Zhang T, Fu C, et al. PPAR\u03b4 inhibition blocks the induction and function of tumor-induced IL-10(+) regulatory B cells and enhances cancer immunotherapy. Cell Discov. 2023;9:54.","journal-title":"Cell Discov"},{"key":"9045_CR22","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1084\/jem.20081163","volume":"205","author":"J Murn","year":"2008","unstructured":"Murn J, Alibert O, Wu N, Tendil S, Gidrol X. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med. 2008;205:3091\u2013103.","journal-title":"J Exp Med"},{"key":"9045_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/eji.1830200225","volume":"20","author":"SH Stein","year":"1990","unstructured":"Stein SH, Phipps RP. Macrophage-secreted prostaglandin E2 potentiates immune complex-induced B cell unresponsiveness. Eur J Immunol. 1990;20:403\u20137.","journal-title":"Eur J Immunol"},{"key":"9045_CR24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1074\/jbc.M110.154971","volume":"286","author":"X Qian","year":"2011","unstructured":"Qian X, Zhang J, Liu J. Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP\/PKA signaling pathway. J Biol Chem. 2011;286:2111\u201320.","journal-title":"J Biol Chem"},{"key":"9045_CR25","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.4049\/jimmunol.1203141","volume":"190","author":"X Qian","year":"2013","unstructured":"Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, et al. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol. 2013;190:5894\u2013902.","journal-title":"J Immunol"},{"key":"9045_CR26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1096\/fasebj.14.5.661","volume":"14","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Csanady M, Gires O, Lang S, Schmitt B, Wollenberg B. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. FASEB J. 2000;14:661\u20138.","journal-title":"FASEB J"},{"key":"9045_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.imlet.2017.01.019","volume":"184","author":"VK Pandey","year":"2017","unstructured":"Pandey VK, Amin PJ, Shankar BS. COX-2 inhibitor prevents tumor-induced downregulation of classical DC lineage-specific transcription factor Zbtb46, resulting in immunocompetent DC and decreased tumor burden. Immunol Lett. 2017;184:23\u201333.","journal-title":"Immunol Lett"},{"key":"9045_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122751","volume":"350","author":"VK Pandey","year":"2024","unstructured":"Pandey VK, Premkumar K, Kundu P, Shankar BS. PGE2-induced miR365\/IL-6\/STAT3 signaling mediates dendritic cell dysfunction in cancer. Life Sci. 2024;350:122751.","journal-title":"Life Sci"},{"key":"9045_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0090-6980(94)90074-4","volume":"47","author":"N Futaki","year":"1994","unstructured":"Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G\/H synthase\/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47:55\u20139.","journal-title":"Prostaglandins"},{"key":"9045_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"key":"9045_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-3565(25)23086-5","volume":"256","author":"GW Carter","year":"1991","unstructured":"Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharm Exp Ther. 1991;256:929\u201337.","journal-title":"J Pharm Exp Ther"},{"key":"9045_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0049-3848(83)90356-0","volume":"4","author":"LA Harker","year":"1983","unstructured":"Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39\u201346.","journal-title":"Thromb Res Suppl"},{"key":"9045_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01514-9","volume":"17","author":"S Testa","year":"2025","unstructured":"Testa S, Pal A, Subramanian A, Varma S, Tang JP, Graham D, et al. SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics. Genome Med. 2025;17:89.","journal-title":"Genome Med"},{"key":"9045_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53706-3","volume":"15","author":"S Punyawatthananukool","year":"2024","unstructured":"Punyawatthananukool S, Matsuura R, Wongchang T, Katsurada N, Tsuruyama T, Tajima M, et al. Prostaglandin E(2)-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. Nat Commun. 2024;15:9464.","journal-title":"Nat Commun"},{"key":"9045_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100299","volume":"23","author":"L Zhou","year":"2020","unstructured":"Zhou L, Tang J, Hu F, Liao Y, Li R, Zhou Y, et al. Effects of different levels of TGF-\u03b2 expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma. J Bone Oncol. 2020;23:100299.","journal-title":"J Bone Oncol"},{"key":"9045_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350496","volume":"54","author":"HF Bradford","year":"2024","unstructured":"Bradford HF, Mauri C. Diversity of regulatory B cells: markers and functions. Eur J Immunol. 2024;54:e2350496.","journal-title":"Eur J Immunol"},{"key":"9045_CR37","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.4049\/jimmunol.169.8.4183","volume":"169","author":"SG Zheng","year":"2002","unstructured":"Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol. 2002;169:4183\u20139.","journal-title":"J Immunol"},{"key":"9045_CR38","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875\u201386.","journal-title":"J Exp Med"},{"key":"9045_CR39","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.4049\/jimmunol.172.9.5149","volume":"172","author":"MC Fantini","year":"2004","unstructured":"Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172:5149\u201353.","journal-title":"J Immunol"},{"key":"9045_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120643","volume":"301","author":"K Premkumar","year":"2022","unstructured":"Premkumar K, Shankar BS. Identification of EPZ004777 and FG2216 as inhibitors of TGF-\u03b21 induced Treg cells by screening a library of epigenetic compounds. Life Sci. 2022;301:120643.","journal-title":"Life Sci"},{"key":"9045_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1242\/jcs.00229","volume":"116","author":"JP Annes","year":"2003","unstructured":"Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116:217\u201324.","journal-title":"J Cell Sci"},{"key":"9045_CR42","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.bbamcr.2009.02.001","volume":"1793","author":"A Rojas","year":"2009","unstructured":"Rojas A, Padidam M, Cress D, Grady WM. TGF-beta receptor levels regulate the specificity of signaling pathway activation and the biological effects of TGF-beta. Biochim Biophys Acta. 2009;1793:1165\u201373.","journal-title":"Biochim Biophys Acta"},{"key":"9045_CR43","doi-asserted-by":"crossref","unstructured":"Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L. Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology. 2020;9:434.","DOI":"10.3390\/biology9120434"},{"key":"9045_CR44","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234:5683\u201399.","journal-title":"J Cell Physiol"},{"key":"9045_CR45","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1158\/0008-5472.CAN-12-3450","volume":"73","author":"S Lindner","year":"2013","unstructured":"Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73:2468\u201379.","journal-title":"Cancer Res"},{"key":"9045_CR46","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/2326-6066.CIR-19-0240","volume":"7","author":"C Lee-Chang","year":"2019","unstructured":"Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, et al. Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol Res. 2019;7:1928\u201343.","journal-title":"Cancer Immunol Res"},{"key":"9045_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-018-0451-6","volume":"6","author":"L Ye","year":"2018","unstructured":"Ye L, Zhang Q, Cheng Y, Chen X, Wang G, Shi M, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6:145.","journal-title":"J Immunother Cancer"},{"key":"9045_CR48","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/cas.14122","volume":"110","author":"Y Mao","year":"2019","unstructured":"Mao Y, Wang Y, Dong L, Zhang Q, Wang C, Zhang Y, et al. Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1(high) Breg cells. Cancer Sci. 2019;110:2700\u201310.","journal-title":"Cancer Sci"},{"key":"9045_CR49","doi-asserted-by":"publisher","first-page":"e14611","DOI":"10.1371\/journal.pone.0014611","volume":"6","author":"SW Sorbye","year":"2011","unstructured":"Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6:e14611.","journal-title":"PLoS One"},{"key":"9045_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135.","journal-title":"Nature"},{"key":"9045_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","volume":"629","author":"M Morotti","year":"2024","unstructured":"Morotti M, Grimm AJ, Hope HC, Arnaud M, Desbuisson M, Rayroux N, et al. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature. 2024;629:426\u201334.","journal-title":"Nature"},{"key":"9045_CR52","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.bbalip.2018.07.003","volume":"1863","author":"A Kashmiry","year":"2018","unstructured":"Kashmiry A, Tate R, Rotondo G, Davidson J, Rotondo D. The prostaglandin EP4 receptor is a master regulator of the expression of PGE. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1297\u2013304.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"9045_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73093-1","volume":"10","author":"FO Oladipupo","year":"2020","unstructured":"Oladipupo FO, Yu CR, Olumuyide E, Jittaysothorn Y, Choi JK, Egwuagu CE. STAT3 deficiency in B cells exacerbates uveitis by promoting expansion of pathogenic lymphocytes and suppressing regulatory B cells (Bregs) and Tregs. Sci Rep. 2020;10:16188.","journal-title":"Sci Rep"},{"key":"9045_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2016.12.031","volume":"389","author":"D Tong","year":"2017","unstructured":"Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang Y, et al. Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2\/PGE2\/STAT3 axis. Cancer Lett. 2017;389:23\u201332.","journal-title":"Cancer Lett"},{"key":"9045_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12079-019-00535-5","volume":"14","author":"P Zhu","year":"2020","unstructured":"Zhu P, Zhou K, Lu S, Bai Y, Qi R, Zhang S. Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2\/PGE2\/STAT3 axis. J Cell Commun Signal. 2020;14:175\u201392.","journal-title":"J Cell Commun Signal"},{"key":"9045_CR56","doi-asserted-by":"publisher","first-page":"e1074376","DOI":"10.1080\/2162402X.2015.1074376","volume":"5","author":"A Lin","year":"2016","unstructured":"Lin A, Wang G, Zhao H, Zhang Y, Han Q, Zhang C, et al. TLR4 signaling promotes a COX-2\/PGE(2)\/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology. 2016;5:e1074376.","journal-title":"Oncoimmunology"},{"key":"9045_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cardiores.2006.09.016","volume":"73","author":"MA Frias","year":"2007","unstructured":"Frias MA, Rebsamen MC, Gerber-Wicht C, Lang U. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy. Cardiovasc Res. 2007;73:57\u201365.","journal-title":"Cardiovasc Res"},{"key":"9045_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/icb.2015.62","volume":"94","author":"V Sreeramkumar","year":"2016","unstructured":"Sreeramkumar V, Hons M, Punz\u00f3n C, Stein JV, Sancho D, Fresno M, et al. Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors. Immunol Cell Biol. 2016;94:39\u201351.","journal-title":"Immunol Cell Biol"},{"key":"9045_CR59","first-page":"552","volume":"15","author":"J Wang","year":"2018","unstructured":"Wang J, Zhang L, Kang D, Yang D, Tang Y. Activation of PGE2\/EP2 and PGE2\/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8. Oncol Lett. 2018;15:552\u20138.","journal-title":"Oncol Lett"},{"key":"9045_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher SB, D\u00f6rr J, de Almeida GP, H\u00f6nninger J, Bayerl F, Hirschberger A, et al. PGE. Nature. 2024;629:417\u201325.","journal-title":"Nature"},{"key":"9045_CR61","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"9045_CR62","doi-asserted-by":"crossref","unstructured":"Largeot A, Pagano G, Gonder S, Moussay E, Paggetti J. The B-side of cancer immunity: the underrated tune. Cells. 2019;8:449.","DOI":"10.3390\/cells8050449"},{"key":"9045_CR63","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1200\/JCO.2013.50.9471","volume":"34","author":"S Theurich","year":"2016","unstructured":"Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, et al. Targeting tumor-infiltrating B cells in cutaneous T-cell lymphoma. J Clin Oncol. 2016;34:e110\u20136.","journal-title":"J Clin Oncol"},{"key":"9045_CR64","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-018-2145-9","volume":"67","author":"JK Winkler","year":"2018","unstructured":"Winkler JK, Schiller M, Bender C, Enk AH, Hassel JC. Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunol Immunother. 2018;67:917\u201324.","journal-title":"Cancer Immunol Immunother"},{"key":"9045_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/PL00006672","volume":"48","author":"E Barbera-Guillem","year":"2000","unstructured":"Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, Feng L, et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B-cell depletion. Cancer Immunol Immunother. 2000;48:541\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"9045_CR66","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2012.27","volume":"20","author":"A Pinc","year":"2012","unstructured":"Pinc A, Somasundaram R, Wagner C, H\u00f6rmann M, Karanikas G, Jalili A, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:1056\u201362.","journal-title":"Mol Ther"},{"key":"9045_CR67","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1172\/JCI59266","volume":"121","author":"M Horikawa","year":"2011","unstructured":"Horikawa M, Minard-Colin V, Matsushita T, Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Investig. 2011;121:4268\u201380.","journal-title":"J Clin Investig"},{"key":"9045_CR68","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","volume":"184","author":"DJ DiLillo","year":"2010","unstructured":"DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184:4006\u201316.","journal-title":"J Immunol"},{"key":"9045_CR69","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1164\/rccm.201010-1738OC","volume":"183","author":"R Sorrentino","year":"2011","unstructured":"Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A, et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med. 2011;183:1369\u201379.","journal-title":"Am J Respir Crit Care Med"},{"key":"9045_CR70","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/annonc\/mdh280","volume":"15","author":"M Aklilu","year":"2004","unstructured":"Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, et al. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004;15:1109\u201314.","journal-title":"Ann Oncol"},{"key":"9045_CR71","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.4049\/jimmunol.1300606","volume":"191","author":"C Lee-Chang","year":"2013","unstructured":"Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel R, et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol. 2013;191:4141\u201351.","journal-title":"J Immunol"},{"key":"9045_CR72","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","volume":"50","author":"CD Funk","year":"2007","unstructured":"Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharm. 2007;50:470\u20139.","journal-title":"J Cardiovasc Pharm"},{"key":"9045_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2024.100475","volume":"15","author":"TMMA Biase","year":"2024","unstructured":"Biase TMMA, Rocha JGM, Silva MT, Ribeiro-Vaz I, Galv\u00e3o TF. Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: a systematic review and meta-analysis. Exploratory Res Clin Soc Pharm. 2024;15:100475.","journal-title":"Exploratory Res Clin Soc Pharm"},{"key":"9045_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000046212","volume":"21","author":"DC Brater","year":"2001","unstructured":"Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001;21:1\u201315.","journal-title":"Am J Nephrol"},{"key":"9045_CR75","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","volume":"5","author":"A Rostom","year":"2007","unstructured":"Rostom A, Muir K, Dub\u00e9 C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of Cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818\u201328.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9045_CR76","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/pds.4183","volume":"26","author":"M Bakhriansyah","year":"2017","unstructured":"Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidemiol Drug Saf. 2017;26:1141\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9045_CR77","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247\u201355.","journal-title":"JAMA"},{"key":"9045_CR78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/apt.14810","volume":"48","author":"C Scarpignato","year":"2018","unstructured":"Scarpignato C, Blandizzi C. Letter: Can the overall gastrointestinal safety of celecoxib be extended to all COX-2-selective agents? Aliment Pharmacol Ther. 2018;48:108\u201310.","journal-title":"Aliment Pharmacol Ther"},{"key":"9045_CR79","doi-asserted-by":"publisher","first-page":"JC1","DOI":"10.7326\/0003-4819-154-2-201101180-02009","volume":"154","author":"EB Gonzalez","year":"2011","unstructured":"Gonzalez EB. Celecoxib reduced GI events more than diclofenac plus omeprazole in patients with osteoarthritis or rheumatoid arthritis. Ann Intern Med. 2011;154:JC1\u20139.","journal-title":"Ann Intern Med"},{"key":"9045_CR80","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","volume":"160","author":"A Whelton","year":"2000","unstructured":"Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465\u201370.","journal-title":"Arch Intern Med"},{"key":"9045_CR81","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","volume":"7","author":"A Whelton","year":"2000","unstructured":"Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7:159\u201375.","journal-title":"Am J Ther"},{"key":"9045_CR82","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Eng J Med. 2005;352:1071-80.","DOI":"10.1056\/NEJMoa050405"},{"key":"9045_CR83","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/ncprheum0120","volume":"2","author":"K Sole","year":"2006","unstructured":"Sole K. Extent of COX2 inhibition might indicate level of cardiovascular risk. Nat Clin Pract Rheumatol. 2006;2:177.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"9045_CR84","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2174\/138161207781368774","volume":"13","author":"J Mart\u00ednez-Gonz\u00e1lez","year":"2007","unstructured":"Mart\u00ednez-Gonz\u00e1lez J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des. 2007;13:2215\u201327.","journal-title":"Curr Pharm Des"},{"key":"9045_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122954","volume":"315","author":"R Huang","year":"2025","unstructured":"Huang R, Yu J, Zhang B, Li X, Liu H, Wang Y. Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment. Biomaterials. 2025;315:122954.","journal-title":"Biomaterials"},{"key":"9045_CR86","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/sj.eye.6700720","volume":"18","author":"E Richtig","year":"2004","unstructured":"Richtig E, Langmann G, M\u00fcllner K, Richtig G, Smolle J. Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas. Eye. 2004;18:619\u201323.","journal-title":"Eye"},{"key":"9045_CR87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495\u2013502.","journal-title":"Nat Biotechnol"},{"key":"9045_CR88","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137.","journal-title":"Omics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09045-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09045-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09045-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:02:28Z","timestamp":1789344148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09045-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9045"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09045-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"795"}}